cilastatin (primaxin) Report issue

Small molecule Approved FDA Priority Review FDA
AACT ChEMBL DrugBank Drug Central KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
PRIMAXIN® is a combination of cilastatin and imipenem. Cilastatin is a specific and reversible renal dehydropeptidase-I inhibitor. Imipenem is a penem antibacterial drug. Since the antibiotic, imipenem, is hydrolyzed by dehydropeptidase-I, which resides in the brush border of the renal tubule, cilastatin is administered with imipenem to block the metabolism and thus the inactivation of imipenem so that antibacterial levels of imipenem can be attained in the urine. However, cilastatin in and of itself does not have any antibacterial activity. It also prevents the metabolism of leukotriene D4 to leukotriene E4 through the inhibition of leukotriene D4 dipeptidase.   NCATS

Chemistry

  • SMILES: CC1(C)C[C@@H]1C(=O)N/C(=C\CCCCSC[C@H](N)C(=O)O)C(=O)O
  • InChIKey: DHSUYTOATWAVLW-WFVMDLQDSA-N
  • Mol. Mass: 358.46
  • ALogP: 1.43
  • ChEMBL Molecules:
    cilastatin  
    cilastatin sodium  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Parenteral
  • Pro Drug: No

Combination drugs

( cilastatin (primaxin), imipenem (primaxin) - other name: imipenem and cilastatin )
|
( cilastatin (primaxin), relebactam (Recarbrio), imipenem (primaxin) - other name: imipenem/cilastatin/relebactam )

Alternative names

cilastatin | cilastatina | cilastatine | cilastatin, imipenem drug combination | cilastatin monosodium | cilastatin sodium | cilastatinum | cilastin | imipenem - cilastatin | imipenem + cilastatin | imipenem-cilastatin | imipenem-cilastatin, sodium salt | (l)-7-(2-amino-2-carboxy-ethylsulfanyl)-2-[(2,2-dimethyl-cyclopropanecarbonyl)-amino]-hept-2-enoic acid | mk 0787-mk 0791 mixture | mk 787-mk 791 mixture | mk-791 | primaxin | thienam | tienam 500 | (z)-7-((r)-2-amino-2-carboxy-ethylsulfanyl)-2-[((s)-2,2-dimethyl-cyclopropanecarbonyl)-amino]-hept-2-enoic acid | zienam | (z)-(s)-6-carboxy-6-[(s)-2,2-dimethylcyclopropanecarboxamido]hex-5-enyl-l-cysteine

Organizations (35)

Research & Development (32)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (4)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (29)

Approved Indications (8)


 

Bacterial Infections (approved 1985)

Endocarditis

Infections

Intraabdominal Infections

Pneumonia

Sepsis

Tuberculosis

Urinary Tract Infections

Experimental Indications - Clinical Trial Phases 1-4 (27)


 

Abdominal Abscess (Phase 2)

Abscess (Phase 3)

Acinetobacter baumannii (Phase 3)

Bacteremia (Phase 3)

Bacterial Infections (Phase 3)

Cellulitis (Phase 3)

Communicable Diseases (Phase 1)

Critical Illness (Phase 4)

Cystic Fibrosis (Phase 4)

Drugs, Investigational (Phase 3)

Fasting (Phase 1)

Febrile Neutropenia (Phase 4)

Healthcare-Associated Pneumonia (Phase 3)

Hematologic Neoplasms (Phase 4)

Infections (Phase 4)

Intraabdominal Infections (Phase 4)

Lymphoma (Phase 2)

Methicillin-Resistant Staphylococcus aureus (Phase 4)

Neoplasms (Phase 2)

Obesity (Phase 4)

Pneumonia (Phase 4)

Pneumonia, Bacterial (Phase 4)

Pneumonia, Ventilator-Associated (Phase 4)

Pyelonephritis (Phase 3)

Sepsis (Phase 1/Phase 2)

Urinary Tract Infections (Phase 3)

Ventilators, Mechanical (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 39
  • # of Trial Organizations: 32

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue